启迪药业(000590) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥67,896,908.56, representing a 10.51% increase year-over-year, and a total revenue of ¥216,410,081.19 for the year-to-date, up 22.54% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2021 was ¥9,866,441.56, a significant increase of 79.67%, with year-to-date net profit reaching ¥39,065,966.12, up 102.14% year-over-year[2] - The basic earnings per share for Q3 2021 was ¥0.0412, reflecting a 79.67% increase, while the diluted earnings per share also stood at ¥0.0412, with a year-to-date figure of ¥0.1631, up 102.11%[2] - Total operating revenue for the third quarter of 2021 reached ¥216,410,081.19, an increase of 22.5% compared to ¥176,598,244.43 in the same period last year[16] - The company's net profit for the period was ¥45,285,119.41, compared to ¥22,882,185.11 in the previous year, indicating a significant growth in profitability[16] - The net profit for Q3 2021 was CNY 39,065,966.12, representing a 102.5% increase compared to CNY 19,325,939.31 in the same period last year[18] - Basic earnings per share for Q3 2021 were CNY 0.1631, compared to CNY 0.0807 in the same quarter last year, marking an increase of 102.5%[18] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥920,937,025.61, marking a 3.23% increase from the end of the previous year[2] - Total assets increased to ¥920,937,025.61 from ¥892,157,636.28 at the end of 2020, representing a growth of 3.3%[14] - Total liabilities decreased to ¥236,987,594.10 from ¥247,274,170.89, a reduction of 4.5%[15] - The company's equity attributable to shareholders was ¥644,883,465.39, with retained earnings showing a deficit of ¥114,550,125.76[27] Cash Flow - The company reported a net cash flow from operating activities of ¥29,855,114.23, which is a decrease of 43.39% compared to the previous period[8] - The cash flow from operating activities showed a net inflow of CNY 29,855,114.23, down from CNY 52,736,033.77 in the previous year, reflecting a decrease of about 43.4%[21] - The company reported cash inflows from investment activities totaling CNY 616,535,923.52, significantly higher than CNY 5,800,200.00 in the prior year[22] - The cash outflow for investment activities was CNY 803,091,080.34, compared to CNY 82,307,562.72 in the same period last year, resulting in a net cash outflow of CNY 186,555,156.82[22] - The company reported a decrease in cash flow from financing activities, with a net outflow of CNY 5,062,792.09 compared to a net inflow of CNY 4,911,111.11 in the previous year[22] Inventory and Expenses - The company’s inventory increased by 52.96% to ¥77,736,992.65, primarily due to an increase in raw material reserves[7] - Research and development expenses for the quarter were ¥5,838,340.59, slightly down from ¥6,554,529.71 in the previous year[16] Other Financial Metrics - The company’s weighted average return on equity was 1.45% for Q3 2021, an increase of 0.59% compared to the previous year[2] - The company’s other income increased by 197.58% to ¥6,385,646.71, mainly due to an increase in government subsidies[7] - The company experienced a significant decrease in cash and cash equivalents, down 47.17% to ¥181,190,054.29, primarily due to the purchase of structured deposits[7] - The company reported a decrease in other payables to ¥42,811,263.61 from ¥51,849,591.49, a decline of 17.5%[15] - The company’s retained earnings improved to -¥75,484,159.64 from -¥114,550,125.76, indicating a reduction in accumulated losses[15] Reporting and Transparency - The company has not undergone an audit for the third-quarter report, indicating that the figures are unaudited[28] - The report was released by the board of directors on October 28, 2021, highlighting the company's commitment to transparency[29]